|
JPH0193801A
(ja)
*
|
1987-10-05 |
1989-04-12 |
Fanuc Ltd |
コントロールプログラムのローディング装置
|
|
GB9114760D0
(en)
*
|
1991-07-09 |
1991-08-28 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9119704D0
(en)
*
|
1991-09-14 |
1991-10-30 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9121028D0
(en)
*
|
1991-10-03 |
1991-11-13 |
Pfizer Ltd |
Therapeutic agents
|
|
US5294612A
(en)
*
|
1992-03-30 |
1994-03-15 |
Sterling Winthrop Inc. |
6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
|
|
DE4211239C2
(de)
*
|
1992-04-03 |
1995-11-16 |
Max Planck Gesellschaft |
Arzneimittel gegen Herz-Kreislauf-Erkrankungen
|
|
GB9218322D0
(en)
*
|
1992-08-28 |
1992-10-14 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9301192D0
(en)
|
1993-06-09 |
1993-06-09 |
Trott Francis W |
Flower shaped mechanised table
|
|
GB9312853D0
(en)
|
1993-06-22 |
1993-08-04 |
Euro Celtique Sa |
Chemical compounds
|
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
JP3726306B2
(ja)
*
|
1994-04-27 |
2005-12-14 |
日産化学工業株式会社 |
ピラゾールカルボン酸誘導体および植物病害防除剤
|
|
US5922751A
(en)
|
1994-06-24 |
1999-07-13 |
Euro-Celtique, S.A. |
Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
|
|
US5591776A
(en)
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
|
US5696159A
(en)
*
|
1994-08-03 |
1997-12-09 |
Cell Pathways, Inc. |
Lactone compounds for treating patients with precancerous lesions
|
|
US5776962A
(en)
*
|
1994-08-03 |
1998-07-07 |
Cell Pathways, Inc. |
Lactone compounds for treating patient with precancerous lesions
|
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9423911D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
KR19980702892A
(ko)
*
|
1995-03-10 |
1998-08-05 |
보먼 메리 피 |
6-아릴 피라졸로[3,4-디]피리미딘-4-온 및 그의 조성물 및 그의사용 방법
|
|
US5656629A
(en)
*
|
1995-03-10 |
1997-08-12 |
Sanofi Winthrop, Inc. |
6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
|
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US6046216A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
|
GB9514473D0
(en)
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
US6166041A
(en)
|
1995-10-11 |
2000-12-26 |
Euro-Celtique, S.A. |
2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
|
|
US6075016A
(en)
|
1996-04-10 |
2000-06-13 |
Euro-Celtique S.A. |
6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
|
|
DE69711882T2
(de)
|
1996-05-10 |
2002-10-31 |
Icos Corp |
Carbolinderivate
|
|
GB9612514D0
(en)
*
|
1996-06-14 |
1996-08-14 |
Pfizer Ltd |
Novel process
|
|
HRP970348A2
(en)
*
|
1996-07-17 |
1998-04-30 |
Bayer Ag |
New nitropyrazole esters, process for their preparation and their use for the preparation of nytropyrazolamides
|
|
USRE37234E1
(en)
*
|
1996-11-01 |
2001-06-19 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
|
|
AU722480B2
(en)
*
|
1996-11-01 |
2000-08-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US5958926A
(en)
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
DE19701277A1
(de)
*
|
1997-01-16 |
1998-07-23 |
Bayer Ag |
Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
|
|
US6723719B1
(en)
*
|
1997-04-25 |
2004-04-20 |
Pfizer Inc |
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
|
|
CA2238283C
(en)
|
1997-05-30 |
2002-08-20 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
|
|
US5858694A
(en)
*
|
1997-05-30 |
1999-01-12 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of cancerous lesions
|
|
US20020025969A1
(en)
*
|
1997-07-09 |
2002-02-28 |
Wolf-Georg Forssmann |
Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
US6472425B1
(en)
|
1997-10-31 |
2002-10-29 |
Nitromed, Inc. |
Methods for treating female sexual dysfunctions
|
|
HU228196B1
(en)
|
1997-11-12 |
2013-01-28 |
Bayer Pharma AG |
2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
|
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
|
EP1371647B1
(en)
*
|
1998-04-20 |
2005-07-13 |
Pfizer Inc. |
Pyridine-3-carboxylic acid derivatives and their use as intermediates
|
|
CA2235642C
(en)
|
1998-05-15 |
2007-11-13 |
Torcan Chemical Ltd. |
Processes for preparing sildenafil
|
|
US6087368A
(en)
*
|
1998-06-08 |
2000-07-11 |
Bristol-Myers Squibb Company |
Quinazolinone inhibitors of cGMP phosphodiesterase
|
|
US6200591B1
(en)
*
|
1998-06-25 |
2001-03-13 |
Anwar A. Hussain |
Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
|
|
DE19829616A1
(de)
|
1998-07-02 |
2000-01-05 |
Bayer Ag |
Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
|
|
DE19834507A1
(de)
*
|
1998-07-31 |
2000-02-03 |
Hexal Ag |
Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
|
|
DE19834506A1
(de)
*
|
1998-07-31 |
2000-02-03 |
Hexal Ag |
Transmucosales therapeutisches System zur Anwendung von Sildenafil
|
|
US6180629B1
(en)
|
1998-08-14 |
2001-01-30 |
Cell Pathways, Inc. |
[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
|
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
|
GB9822238D0
(en)
*
|
1998-10-12 |
1998-12-09 |
Pfizer Ltd |
Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
|
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
|
US6130053A
(en)
*
|
1999-08-03 |
2000-10-10 |
Cell Pathways, Inc. |
Method for selecting compounds for inhibition of neoplastic lesions
|
|
GB9823102D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
UA67802C2
(uk)
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
|
GB9823101D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
DE69911448T2
(de)
*
|
1998-10-23 |
2004-04-08 |
Pfizer Inc. |
Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
|
|
GB9823103D0
(en)
*
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
KR100353014B1
(ko)
*
|
1998-11-11 |
2002-09-18 |
동아제약 주식회사 |
발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
|
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
EP1002798A1
(en)
*
|
1998-11-20 |
2000-05-24 |
Orchid Chemicals & Pharmaceuticals Ltd. |
An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative
|
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
AU3347300A
(en)
*
|
1999-01-28 |
2000-08-18 |
Sepracor, Inc. |
Desmethylsildenafil compositions and methods
|
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
|
WO2000051614A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferases
|
|
WO2000078760A1
(fr)
*
|
1999-06-21 |
2000-12-28 |
The Biochemical Pharmaceutical Factory Of Zhuhai Sez |
Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
|
|
CN1094492C
(zh)
*
|
1999-06-21 |
2002-11-20 |
杭州神鹰医药化工有限公司 |
西地那非的制备方法
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
CN1077108C
(zh)
*
|
1999-07-13 |
2002-01-02 |
成都地奥制药集团有限公司 |
用于制备药物昔多芬的前体化合物
|
|
IL130968A
(en)
*
|
1999-07-15 |
2002-12-01 |
Shmuel Simon |
Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
|
|
ES2166270B1
(es)
*
|
1999-07-27 |
2003-04-01 |
Almirall Prodesfarma Sa |
Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
|
|
EP1077214A1
(en)
*
|
1999-08-16 |
2001-02-21 |
Orchid Chemicals & Pharmaceuticals Ltd. |
An improved process for preparing a pyrazolopyrimidinone derivative
|
|
WO2001019827A1
(en)
*
|
1999-09-13 |
2001-03-22 |
Cipla Ltd. |
A novel process for the synthesis of sildenafil citrate
|
|
TWI265925B
(en)
|
1999-10-11 |
2006-11-11 |
Pfizer |
Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
|
|
NZ517324A
(en)
*
|
1999-10-11 |
2003-09-26 |
Pfizer |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
|
|
GB9924020D0
(en)
|
1999-10-11 |
1999-12-15 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
ES2231311T3
(es)
*
|
1999-12-24 |
2005-05-16 |
Bayer Healthcare Ag |
Triazolotriazinonas y su uso.
|
|
AU2365001A
(en)
|
1999-12-24 |
2001-07-09 |
Bayer Aktiengesellschaft |
Isoxazolo pyrimidinones and the use thereof
|
|
IL150022A0
(en)
|
1999-12-24 |
2002-12-01 |
Bayer Ag |
Imidazo [1,3,5] triazinones and the use thereof
|
|
KR100358083B1
(ko)
*
|
2000-02-17 |
2002-10-25 |
에스케이케미칼주식회사 |
피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
|
|
US6555547B1
(en)
|
2000-02-28 |
2003-04-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
|
AU2000254308A1
(en)
*
|
2000-05-17 |
2001-11-26 |
Sk Chemicals Co., Ltd. |
Pyrazolopyrimidinone derivatives, process for their preparation and their use
|
|
GB0015462D0
(en)
*
|
2000-06-22 |
2000-08-16 |
Pfizer Ltd |
Novel process for the preparation of pyrazolopyrimidinones
|
|
US6730786B2
(en)
*
|
2000-06-22 |
2004-05-04 |
Pfizer Inc |
Process for the preparation of pyrazolopyrimidinones
|
|
US6667398B2
(en)
|
2000-06-22 |
2003-12-23 |
Pfizer Inc |
Process for the preparation of pyrazolopyrimidinones
|
|
PL360299A1
(en)
*
|
2000-06-22 |
2004-09-06 |
Pfizer Inc. |
Novel process for the preparation of pyrazolopyrimidinones
|
|
KR100377782B1
(ko)
*
|
2000-06-23 |
2003-03-29 |
동아제약 주식회사 |
발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
|
|
EP1176142A1
(en)
*
|
2000-07-28 |
2002-01-30 |
Pfizer Inc. |
Process for the preparation of pyrazoles
|
|
US6809200B2
(en)
|
2000-07-28 |
2004-10-26 |
Pfizer Inc. |
Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
|
|
US6407259B1
(en)
|
2000-07-28 |
2002-06-18 |
Pfizer Inc. |
Process for the preparation of pyrazoles
|
|
WO2002013798A2
(en)
*
|
2000-08-11 |
2002-02-21 |
Pfizer Limited |
Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
|
|
PE20020394A1
(es)
|
2000-08-18 |
2002-06-21 |
Agouron Pharma |
Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
|
|
AU2000267375A1
(en)
*
|
2000-08-23 |
2002-03-04 |
Lg Life Sciences Ltd. |
Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
EP1211313A3
(en)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation of PDE11A activity
|
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
|
SE0004780D0
(sv)
|
2000-12-22 |
2000-12-22 |
Jordanian Pharmaceutical Mfg & |
Novel compunds
|
|
DE10118306A1
(de)
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
|
|
CN1127506C
(zh)
*
|
2001-06-29 |
2003-11-12 |
刘宝顺 |
一种治疗阳痿的新化合物
|
|
US6479493B1
(en)
|
2001-08-23 |
2002-11-12 |
Cell Pathways, Inc. |
Methods for treatment of type I diabetes
|
|
EP1421084B1
(en)
|
2001-08-28 |
2008-05-14 |
Schering Corporation |
Polycyclic guanine phosphodiesterase v inhibitors
|
|
DE10155018A1
(de)
*
|
2001-11-07 |
2003-07-10 |
Berolina Drug Dev Ab Svedala |
Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
|
|
US6943171B2
(en)
|
2001-11-09 |
2005-09-13 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase V inhibitors
|
|
EP1454897B1
(en)
|
2001-12-13 |
2007-10-10 |
Asubio Pharma Co., Ltd. |
Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
|
|
CA2469075C
(en)
|
2001-12-20 |
2011-09-13 |
Applied Research Systems Ars Holding N.V. |
Pyrrolidine derivatives as prostaglandin modulators
|
|
GB0202282D0
(en)
|
2002-01-31 |
2002-03-20 |
Pfizer Ltd |
Treatment of male sexual dysfunction
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
KR100435514B1
(ko)
*
|
2002-03-22 |
2004-06-10 |
한미약품 주식회사 |
실데나필 젖산염의 속효제형
|
|
DE60237425D1
(de)
*
|
2002-03-28 |
2010-10-07 |
Univerzita Palackeho V Olomouc |
PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
JP2005529927A
(ja)
*
|
2002-05-23 |
2005-10-06 |
ファイザー インコーポレイテッド |
新規な組み合わせ
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7119200B2
(en)
*
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
AU2003303041B2
(en)
|
2002-12-13 |
2008-07-24 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2004072079A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Pfizer Limited |
Hydrated and anhydrous sildenafil hemi-citrate compound
|
|
RS52730B
(sr)
|
2003-05-22 |
2013-08-30 |
Takeda Gmbh |
Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
|
|
JP2006219373A
(ja)
|
2003-06-13 |
2006-08-24 |
Daiichi Asubio Pharma Co Ltd |
Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
|
|
CA2537916A1
(en)
*
|
2003-09-03 |
2005-03-31 |
Neurogen Corporation |
5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
|
|
EP1779852A3
(en)
*
|
2004-01-05 |
2007-05-09 |
Teva Pharmaceutical Industries Ltd. |
Processes for the production of sildenafil base and citrate salt
|
|
DE602005004966T2
(de)
*
|
2004-01-05 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Prozesse zur herstellung von sildenafil-base und zitratsalz
|
|
AU2005277384B2
(en)
*
|
2004-08-17 |
2011-11-17 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
|
DE102005009240A1
(de)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
|
UA84688C2
(uk)
*
|
2005-04-15 |
2008-11-25 |
Виктор Павлович Кутняк |
Засіб для лікування еректильної дисфункції
|
|
CN101163476A
(zh)
|
2005-04-19 |
2008-04-16 |
尼科梅德有限责任公司 |
用于治疗肺动脉高血压的罗氟司特
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
DE102006043443A1
(de)
|
2006-09-15 |
2008-03-27 |
Bayer Healthcare Ag |
Neue aza-bicyclische Verbindungen und ihre Verwendung
|
|
US8071765B2
(en)
|
2006-12-21 |
2011-12-06 |
Topharman Shanghai Co., Ltd. |
Process for the preparation of sildenafil and intermediates thereof
|
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US8034782B2
(en)
|
2008-07-16 |
2011-10-11 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
ES2310144B1
(es)
|
2007-06-15 |
2010-01-12 |
Galenicum Health, S.L. |
Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
|
|
KR20120033357A
(ko)
|
2007-10-23 |
2012-04-06 |
테바 파마슈티컬 인더스트리즈 리미티드 |
다사티닙 다형체 및 이의 제조 방법
|
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
|
US20110244050A1
(en)
|
2008-12-12 |
2011-10-06 |
Siegfried Rhein S.A. De C.V. |
Pulsed-release sildenafil composition and method for preparing said composition
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
WO2010074783A1
(en)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
SI2604608T1
(sl)
|
2009-11-27 |
2015-12-31 |
Adverio Pharma Gmbh |
Postopek izdelave metil-(4,6-diamino-2(1-(2-fluorobenzil)-1H-pirazolo (3,4-b)piridin-3-il)-pirimidin-5-il)metil karbamata in njegovo čiščenje za uporabo kot farmacevtsko sredstvo
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
CN101870699B
(zh)
*
|
2010-04-06 |
2013-11-20 |
漆又毛 |
苯磺酰基哌嗪衍生物
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
MX2010006227A
(es)
|
2010-06-07 |
2011-12-14 |
World Trade Imp Exp Wtie Ag |
Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
|
|
WO2012000634A1
(de)
|
2010-06-29 |
2012-01-05 |
Georg Bambach |
Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
|
|
CN101891747B
(zh)
*
|
2010-07-02 |
2012-04-25 |
张南 |
抑制5型磷酸二酯酶的化合物及制备方法
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
CN102134242B
(zh)
*
|
2011-01-21 |
2013-08-28 |
浙江大德药业集团有限公司 |
一种用于治疗阳痿的快速长效的化合物
|
|
EP2681236B1
(en)
|
2011-03-01 |
2018-01-03 |
Synergy Pharmaceuticals Inc. |
Process of preparing guanylate cyclase c agonists
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
JP6189315B2
(ja)
|
2011-11-25 |
2017-08-30 |
アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法
|
|
BR112015003380A2
(pt)
*
|
2012-08-23 |
2017-07-04 |
Mitsubishi Tanabe Pharma Corp |
composto de pirazolopirimidina
|
|
BR112015019571A2
(pt)
|
2013-02-21 |
2017-07-18 |
Adverio Pharma Gmbh |
formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila
|
|
EP3718557A3
(en)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
|
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014274812B2
(en)
|
2013-06-05 |
2018-09-27 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
|
KR20220147691A
(ko)
|
2013-08-09 |
2022-11-03 |
알데릭스, 인코포레이티드 |
인산염 수송을 억제하기 위한 화합물 및 방법
|
|
CN103755709B
(zh)
*
|
2014-01-15 |
2016-05-25 |
广东药学院 |
西地那非衍生物的微波辅助制备方法
|
|
CN105017255A
(zh)
*
|
2014-04-25 |
2015-11-04 |
浙江泰康药业集团有限公司 |
西地那非制备工艺
|
|
JP6687550B2
(ja)
|
2014-06-23 |
2020-04-22 |
セルジーン コーポレイション |
肝疾患又は肝機能異常を治療するためのアプレミラスト
|
|
CN107955009A
(zh)
*
|
2015-07-23 |
2018-04-24 |
青岛华之草医药科技有限公司 |
一种制备治疗男性***功能障碍的化合物的方法
|
|
US10570137B2
(en)
|
2015-11-16 |
2020-02-25 |
Topadur Pharma Ag |
2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
|
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
AU2018287159A1
(en)
|
2017-06-21 |
2020-01-16 |
Transgene |
Personalized vaccine
|
|
JP2021516957A
(ja)
|
2018-03-07 |
2021-07-15 |
トランジェーヌＴｒａｎｓｇｅｎｅ |
パラポックスウイルスベクター
|
|
AU2019319004A1
(en)
|
2018-08-06 |
2021-03-25 |
Nicox S.A. |
Nitric oxide releasing phosphodiesterase type 5 inhibitor
|
|
SE542968C2
(en)
|
2018-10-26 |
2020-09-22 |
Lindahl Anders |
Treatment of osteoarthritis
|
|
MX2021005892A
(es)
|
2018-11-28 |
2021-06-23 |
Topadur Pharma Ag |
Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos.
|
|
BR112021012630A2
(pt)
|
2018-12-28 |
2022-12-13 |
Transgene Sa |
Poxvírus modificado, método para produzir o poxvírus modificado e composição
|
|
EP3972599A1
(en)
|
2019-05-21 |
2022-03-30 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|